Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural...

July 14, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026

Feature

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

OS Therapies (NYSE American: OSTX) is addressing the urgent need for innovative therapies to kill aggressive cancers that express HER2, including osteosarcoma—a rare and often fatal bone cancer—as well as other solid...

June 16, 2026

Feature

Healing the Hero rewiring trauma through neurolinguistic programming

The nonprofit organization Healing the Hero is bringing hope to U.S. military personnel, veterans, first responders, and Gold Star Families by leveraging neurolinguistic programming (NLP)-informed methods to directly...

June 9, 2026

NEWS

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

BTIG starts coverage of two TMS companies at buy, sees anticipated psilocybin therapy approval as potential catalyst for both

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

OS Therapies aims to activate the immune system to combat aggressive cancers in human and canine patients

Healing the Hero rewiring trauma through neurolinguistic programming

NEWS

Casp-Aid appoints Mika Guerard as VP, Head of Drug Development

BTIG starts coverage of two TMS companies at buy, sees anticipated psilocybin therapy approval as potential catalyst for both

LIR and OH sign agreement to advance roadmap for transdermal obesity pipeline

Dimerix acquires Phase 2-ready asset for acute kidney injury

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Brookline starts Perimeter at buy; PT C$1.54

Myricx to be acquired by Novartis for $1.5B

Just a few of the companies we’ve highlighted along the way

Subscribe